Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and Erlotinib …

T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
被引用次数：299 相关文章

Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib …

T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of Clinical …, 2014 - europepmc.org
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in
patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial …
[PDF] researchgate.net

[PDF][PDF] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second-or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel …

T Kawaguchi, M Ando, K Asami, Y Okano, M Fukuda… - J Clin …, 2014 - researchgate.net
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …

[引用][C] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second-or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel …

T KAWAGUCHI, M ANDO… - Journal of clinical …, 2014 - pascal-francis.inist.fr
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy
in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung …

Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib …

T Kawaguchi, M Ando, K Asami… - Journal of clinical …, 2014 - pubmed.ncbi.nlm.nih.gov
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non-small-cell lung cancer (NSCLC) in an epidermal growth factor …

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second-or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and …

T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of Clinical …, 2014 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> To investigate the efficacy of erlotinib
versus docetaxel in previously treated patients with advanced non–small-cell lung cancer …

[引用][C] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second-or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel …

T KAWAGUCHI, M ANDO… - Journal of …, 2014 - American Society of Clinical …